7NS0 Stock Chart & Stats
€5.01
€0.00(0.00%)
At close: 4:00 PM EDT
€5.01
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€5.01 - €5.36
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€306.13M
Enterprise Value€234.29
Total Cash (Recent Filing)€132.63M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
BetaN/A
Next Earnings
Aug 25, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.06
Shares Outstanding173,579,670
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.01
Price to Sales (P/S)0.00
P/FCF Ratio-12.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€6.11Price Target Upside21.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.21
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthPalisade's near-zero debt and sizable equity position give the company durable financial flexibility during its clinical development phase. Low leverage reduces insolvency risk, supports continued R&D spending, and allows the firm to pursue partnerships or staged financings without immediate distress for the next several months.
Clinical Partnership And FundingA partnership that accelerates Phase 2 enrollment plus a $3.0M private placement materially supports program timelines and near-term runway. Structural benefits include faster data readouts, partner validation for the science, and incremental non-dilutive or minimally dilutive capital to de-risk development milestones.
Governance And Capital FlexibilityShareholder approval of charter amendments and equity plans signals governance stability and grants management strategic flexibility to raise capital or use equity for talent retention. This structural capability supports executing a capital-intensive clinical plan and aligning long-term incentives with development milestones.
Bears Say
Lack Of Revenue & Widening LossesThe absence of meaningful revenue and persistent, widening operating losses mean Palisade remains wholly dependent on external funding until commercial product success. Negative profitability (large TTM losses) drives negative returns on equity and constrains reinvestment capacity until clinical progress translates into revenue or value-accretive partnerships.
Persistent Negative Cash FlowSustained negative operating and free cash flow indicates ongoing burn to fund R&D, requiring continuing financing to preserve operations. Over 2-6 months this reduces runway, forces management to prioritize programs, and increases reliance on dilutive equity or partnership milestones to avoid disrupting clinical timelines.
Dilution Risk From Authorized Share IncreaseWhile the share-authority increase gives financing flexibility, it structurally raises the risk of future equity issuance and dilution. For a pre-revenue biotech, access to a large share pool makes shareholder dilution more likely as management funds trials, which can reduce per-share economics and investor returns absent clear revenue or partnership outcomes.
Palisade Bio News
7NS0 FAQ
What was Palisade Bio, Inc.’s price range in the past 12 months?
Palisade Bio, Inc. lowest stock price was €5.01 and its highest was €5.36 in the past 12 months.
What is Palisade Bio, Inc.’s market cap?
Palisade Bio, Inc.’s market cap is €306.13M.
When is Palisade Bio, Inc.’s upcoming earnings report date?
Palisade Bio, Inc.’s upcoming earnings report date is Aug 25, 2026 which is in 25 days.
How were Palisade Bio, Inc.’s earnings last quarter?
Palisade Bio, Inc. released its earnings results on May 12, 2026. The company reported -€0.043 earnings per share for the quarter, missing the consensus estimate of -€0.037 by -€0.006.
Is Palisade Bio, Inc. overvalued?
According to Wall Street analysts Palisade Bio, Inc.’s price is currently Undervalued.
Does Palisade Bio, Inc. pay dividends?
Palisade Bio, Inc. does not currently pay dividends.
What is Palisade Bio, Inc.’s EPS estimate?
Palisade Bio, Inc.’s EPS estimate is -0.05.
How many shares outstanding does Palisade Bio, Inc. have?
Palisade Bio, Inc. has 173,579,670 shares outstanding.
What happened to Palisade Bio, Inc.’s price movement after its last earnings report?
Palisade Bio, Inc. reported an EPS of -€0.043 in its last earnings report, missing expectations of -€0.037. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Palisade Bio, Inc.?
Currently, no hedge funds are holding shares in DE:7NS0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Palisade Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€6.11 (21.99% Upside)
€6.11 (21.99% Upside)
Blogger Sentiment
Bullish
DE:7NS0 Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $249.7K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
75.67%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
1527.78%
Trailing 12-Months
Company Description
Palisade Bio, Inc.
Palisade Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to identifying, advancing, and bringing to market orally administered treatments for significant conditions stemming from a compromised gastrointestinal mucosal barrier. The company's primary therapeutic candidate, LB1148, is an oral liquid formulation designed to inhibit digestive enzymes. Its goal is to safeguard gut integrity when the intestine experiences stress due to factors such as diminished blood supply, infections, or surgical procedures. Established in 2005, the company maintains its headquarters in Carlsbad, California.
7NS0 Stock 12 Month Forecast
Average Price Target
€6.11
▲(21.99% Upside)
Technical Analysis
Corbus Pharmaceuticals
―
Eledon Pharmaceuticals
―
―
Orchestra BioMed Holdings
―
Pyxis Oncology
―